This is a clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol
hydrochloride, which is an already licensed drug for the treatment of respiratory conditions
(such as a common cold) in many European countries. The aim of this trial is to find out
whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to
evaluate it's safety and tolerability.